ATC Group: J06BD Antiviral monoclonal antibodies

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J06BD in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J06 Immune sera and immunoglobulins
3 J06B Immunoglobulins
4 J06BD Antiviral monoclonal antibodies

Group J06BD contents

Code Title
J06BD01 Palivizumab
J06BD02 Motavizumab
J06BD03
J06BD04
J06BD05
J06BD06
J06BD07
J06BD08

Active ingredients in J06BD

Active Ingredient Description
Ansuvimab

Ansuvimab is a recombinant human monoclonal antibody with antiviral activity against Zaire ebolavirus.

Casirivimab and imdevimab

Casirivimab (IgG1Îș) and imdevimab (IgG1λ) are two recombinant human monoclonal antibodies which are unmodified in the Fc regions. Casirivimab and imdevimab bind to non-overlapping epitopes of the spike protein receptor binding domain (RBD) of SARS-CoV-2. This prevents RBD binding to the human ACE2 receptor, so preventing virus entry into cells.

Nirsevimab

Nirsevimab is a recombinant neutralising human IgG1Äž long-acting monoclonal antibody to the prefusion conformation of the RSV F protein which has been modified with a triple amino acid substitution (YTE) in the Fc region to extend serum half-life. Nirsevimab inhibits the essential membrane fusion step in the viral entry process, neutralising the virus and blocking cell-to-cell fusion.

Palivizumab

Palivizumab is a humanised IgG1Îș monoclonal antibody directed to an epitope in the A antigenic site of the fusion protein of respiratory syncytial virus (RSV). This humanised monoclonal antibody is composed of human (95%) and murine (5%) antibody sequences. It has potent neutralising and fusion-inhibitory activity against both RSV subtype A and B strains.

Regdanvimab

Regdanvimab is a recombinant human IgG1 monoclonal antibody that binds to the receptor binding domain (RBD) of the spike(s) protein of SARS-CoV-2 consequently blocking cellular entry and SARS-CoV-2 infection.

Sotrovimab

Sotrovimab is a dual action, engineered human IgG1 mAb that binds to a conserved epitope on the spike protein receptor binding domain of SARS-CoV-2. It is used for the treatment of symptomatic adults and adolescents with acute covid-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe covid infection.

Tixagevimab and Cilgavimab

Tixagevimab and cilgavimab are two recombinant human IgG1 monoclonal antibodies, with amino acid substitutions in the Fc regions, to extend antibody half-life and to reduce antibody effector function and potential risk of antibody-dependent enhancement of disease. Tixagevimab and cilgavimab can simultaneously bind to non-overlapping regions of the spike protein receptor binding domain (RBD) of SARS-CoV-2. Tixagevimab, cilgavimab and their combination bind to spike blocking its interaction with the human ACE2 receptor, resulting in a blockade of virus entry.

Related product monographs

Title Information Source Document Type  
BEYFORTUS Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
EBANGA Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR
EVUSHELD Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
REGKIRONA Concentrate for solution for infusion MPI, EU: SmPC
REGKIRONA Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
RONAPREVE Solution for injection/infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
SYNAGIS Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
XEVUDY Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC